536565 NOVELIX

Novelix Pharmaceuticals Share Price

 

 

Start SIP in NOVELIX

Start SIP

Performance

  • Low
  • ₹63
  • High
  • ₹67
  • 52 Week Low
  • ₹25
  • 52 Week High
  • ₹70
  • Open Price₹66
  • Previous Close₹64
  • Volume4,547
  • 50 DMA₹59.24
  • 100 DMA₹55.06
  • 200 DMA₹46.46

Investment Returns

  • Over 1 Month + 15.47%
  • Over 3 Month -6.17%
  • Over 6 Month + 51.85%
  • Over 1 Year + 147.34%

Smart Investing Starts Here Start SIP with Novelix Pharmaceuticals for Steady Growth!

Invest Now

Novelix Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 60.5
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 110
  • P/B Ratio
  • 3.8
  • Average True Range
  • 3.92
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • 1.21
  • RSI
  • 56.37
  • MFI
  • 59.11

Novelix Pharmaceuticals Financials

Novelix Pharmaceuticals Technicals

EMA & SMA

Current Price
₹62.70
-1.51 (-2.35%)
pointer
  • Bearish Moving Average 3
  • Bullish Moving Average 13
  • 20 Day
  • ₹61.37
  • 50 Day
  • ₹59.24
  • 100 Day
  • ₹55.06
  • 200 Day
  • ₹46.46

Resistance and Support

64.15 Pivot Speed
  • R3 70.31
  • R2 68.65
  • R1 65.81
  • S1 61.31
  • S2 59.65
  • S3 56.81

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Novelix Pharmaceuticals Ltd has an operating revenue of Rs. 127.97 Cr. on a trailing 12-month basis. An annual revenue growth of 578% is outstanding, Pre-tax margin of 0% needs improvement, ROE of 0% is poor and needs improvement. The company has a debt to equity of 53%, which is bit higher. The stock from a technical standpoint is comfortably placed above its key moving averages, around 8% and 41% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 8% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 75 which is a FAIR score but needs to improve its earnings, a RS Rating of 95 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 119 indicates it belongs to a poor industry group of Food-Packaged and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Novelix Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-12 Quarterly Results
2025-11-13 Quarterly Results
2025-08-14 Quarterly Results & A.G.M.
2025-06-24 Others Inter alia, to consider and approve 1. The conversion of Warrants into Equity Shares of the Company.
2025-05-27 Audited Results

Novelix Pharmaceuticals F&O

Novelix Pharmaceuticals Shareholding Pattern

50.8%
44%
5.2%

Novelix Pharmaceuticals FAQs

Novelix Pharmaceuticals share price is ₹62 As on 20 February, 2026 | 03:07

The Market Cap of Novelix Pharmaceuticals is ₹110.4 Cr As on 20 February, 2026 | 03:07

The P/E ratio of Novelix Pharmaceuticals is 60.5 As on 20 February, 2026 | 03:07

The PB ratio of Novelix Pharmaceuticals is 3.8 As on 20 February, 2026 | 03:07

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23